Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | CASP3 | P42574 | 2/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.58 |
| ▸ | MAOB | P27338 | 8/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 6/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | SLC26A4 | O43511 | 3/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958563 | 1.00 | L3MBTL1 (0.65) | L3MBTL1PKMCASP3SENP8SENP7 | |
| SCHEMBL24484859 | 0.82 | MAPT (0.63) | L3MBTL1PKMCASP3SENP8SENP7 | |
| SCHEMBL25707033 | 0.80 | KDM4E (0.40) | L3MBTL1PKMNPC1RAB9AKMT2A | |
| SCHEMBL5746156 | 0.79 | CASP3 (0.63) | L3MBTL1PKMCASP3SENP8SENP7 | |
| SCHEMBL720239 | 0.79 | CASP3 (0.70) | L3MBTL1PKMCASP3SENP8SENP7 | |
| SCHEMBL719690 | 0.78 | L3MBTL1 (0.60) | L3MBTL1PKMCASP3SENP8SENP7 | |
| SCHEMBL717257 | 0.78 | KDM4E (0.60) | L3MBTL1CASP3SENP8SENP7SENP6 | |
| SCHEMBL718464 | 0.77 | L3MBTL1 (0.58) | L3MBTL1PKMCASP3SENP8SENP7 | |
| SCHEMBL9727459 | 0.77 | L3MBTL1 (0.58) | L3MBTL1PKMCASP3SENP8SENP7 | |
| SCHEMBL717397 | 0.77 | CASP3 (0.61) | L3MBTL1PKMCASP3SENP8SENP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473283-B2 | Compounds and their use | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-11-18 | — | — | US | disclosed |
| CN-115151541-B | Novel compounds and uses thereof | 德彪药业国际股份公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| EP-4077324-A1 | NOVEL COMPOUNDS AND THEIR USE | Debiopharm International SA (CH) | 2022-10-26 | — | — | EP | disclosed |
| CN-115151541-A | Novel compound and use thereof | 德彪药业国际股份公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021123372-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021123372-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2021-06-24 | — | — | WO | disclosed |
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | L3MBTL1 4088/4885PKM 2662/4885CASP3 489/4885 |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | LSS, PGLS, LDHB | L3MBTL1 191/4885PKM 1498/4885CASP3 1157/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | L3MBTL1 4088/4885PKM 2662/4885CASP3 489/4885 |
| US-12473283-B2 | Compounds and their use | LSS, PGLS, LDHB | L3MBTL1 125/4885PKM 1167/4885CASP3 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.